ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
A look at big oncology deals since 2016 finds outright success stories hard to come by.